Daily Cardiology Research Analysis
Across cardiology, three high-impact studies shape practice. An individual patient data meta-analysis shows that complete revascularization in acute myocardial infarction reduces cardiovascular death and myocardial infarction versus culprit-only PCI. A phase 3 randomized trial reports that intracoronary allogeneic mesenchymal stem cells soon after STEMI lower subsequent heart failure and HF readmissions. A Cochrane review finds low-dose colchicine reduces myocardial infarction and stroke without
Summary
Across cardiology, three high-impact studies shape practice. An individual patient data meta-analysis shows that complete revascularization in acute myocardial infarction reduces cardiovascular death and myocardial infarction versus culprit-only PCI. A phase 3 randomized trial reports that intracoronary allogeneic mesenchymal stem cells soon after STEMI lower subsequent heart failure and HF readmissions. A Cochrane review finds low-dose colchicine reduces myocardial infarction and stroke without increasing serious adverse events in secondary prevention.
Research Themes
- Complete revascularization strategies in multivessel AMI
- Post-MI biologic therapy to prevent heart failure
- Anti-inflammatory therapy (colchicine) in secondary prevention
Selected Articles
1. Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials.
Pooling individual patient data from six randomized trials (n=8,836), complete revascularization reduced the composite of cardiovascular death or new myocardial infarction (HR 0.76) and cardiovascular death alone (HR 0.76) versus culprit-only PCI over a median 36 months. All-cause mortality and new MI were also lower without excess non-cardiovascular death.
Impact: This IPD meta-analysis provides definitive, patient-level evidence that complete revascularization in AMI lowers hard outcomes, including cardiovascular death, supporting practice and guideline refinement.
Clinical Implications: For multivessel AMI, prioritize complete revascularization rather than culprit-only PCI when feasible, anticipating reductions in cardiovascular death and MI. Programs should streamline staged or index-procedure strategies and integrate physiology/imaging to guide non-culprit PCI.
Key Findings
- Complete revascularization reduced cardiovascular death or new MI (HR 0.76; 95% CI 0.67–0.87).
- Cardiovascular death alone was lower with complete revascularization (HR 0.76; 95% CI 0.62–0.93).
- All-cause mortality decreased (HR 0.85; 95% CI 0.73–0.99) with no increase in non-cardiovascular death (HR 0.98).
- New myocardial infarction was reduced (HR 0.76; 95% CI 0.65–0.90) over median 36 months.
Methodological Strengths
- Individual patient data meta-analysis enabling harmonized definitions and time-to-event modeling
- Large aggregated sample (n=8,836) across six randomized trials with robust follow-up
Limitations
- Potential heterogeneity in non-culprit lesion selection criteria and timing (index vs staged PCI)
- Trial-era variations in stents, antithrombotics, and physiology/imaging use may affect generalizability
Future Directions: Define optimal timing and selection of non-culprit PCI (physiology/imaging-guided) and evaluate contemporary antithrombotic regimens with complete revascularization.
BACKGROUND: In patients presenting with acute coronary syndromes and multivessel coronary artery disease, the question of whether to undertake a strategy of complete revascularisation in cases in which percutaneous coronary intervention (PCI) is performed routinely on non-culprit lesions (in addition to the culprit lesion) or whether to restrict PCI only to the culprit lesion is a common dilemma. The Complete Revascularisation Trialists' Collaboration aimed to determine, based on the totality of data from randomised trials, the effect of a complete r
2. Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8).
In 396 analyzable patients after STEMI with LVEF<40%, intracoronary allogeneic Wharton’s jelly–derived MSCs (3–7 days post-MI) reduced incident heart failure over a median 33.2 months and lowered HF readmissions, with a favorable effect on a composite of cardiovascular outcomes versus standard care.
Impact: This phase 3 randomized trial advances a regenerative approach that meaningfully lowers post-MI heart failure, a major driver of morbidity, suggesting a potential adjunctive therapy after primary PCI.
Clinical Implications: In high-risk STEMI survivors with reduced LVEF, early intracoronary allogeneic MSC infusion may lower HF onset and rehospitalizations. If confirmed across regions and manufacturing platforms, structured pathways for cell delivery and monitoring could be incorporated into post-MI care.
Key Findings
- Intracoronary allogeneic Wharton’s jelly–derived MSCs within 3–7 days post-STEMI reduced incident heart failure over median 33.2 months.
- HF rehospitalizations were lower in the MSC arm; a composite of cardiovascular mortality and HF/MI readmission favored MSCs.
- Trial randomized 420, analyzed 396 (136 MSC vs 260 control); early LVEF trajectory was compared over 6 months.
Methodological Strengths
- Phase 3 randomized design with prespecified clinical endpoints and multi-year follow-up
- Early post-MI intracoronary delivery standardized across three tertiary centers
Limitations
- Single-country, three-center trial may limit generalizability; blinding details not specified
- Cell manufacturing and product heterogeneity may affect scalability and reproducibility
Future Directions: Confirm efficacy and safety in multinational, blinded trials with standardized manufacturing; define optimal dose, timing, and patient selection; integrate imaging/biomarker endpoints for remodeling.
OBJECTIVE: To assess the effect of intracoronary infusion of mesenchymal stem cells on the development of post-myocardial infarction heart failure. DESIGN: Phase 3 randomised clinical trial. SETTING: Three tertiary hospitals in Shiraz, Iran. PARTICIPANTS: 420 patients with a first ST segment elevation acute myocardial infarction and left ventricular ejection fraction <40% were enrolled and randomised in a 1:2 ratio to receive intervention or standard care. INTERVENTION: Intracoronary infusion of allogenic Wharton's jelly derived mesenchymal stem cells within 3-7 days of acute myocardial infarction in addition to standard care. MAIN OUTCOME MEASURES: The primary endpoint was incidence of heart failure. Secondary endpoints included readmission to hospital for heart failure, all cause mortality, cardiovascular mortality, and readmission to hospital for myocardial infarction. Changes in left ventricular ejection fraction within six months post-myocardial infarction were compared between groups. RESULTS: A total of 396 patients (136 in the intervention group and 260 in the control group) were included in the final analysis, with a median follow-up of 33.2 months. Intracoronary infusion of mesenchymal stem cells had a preventive effect for incidence of heart failure (2.77
3. Colchicine for the secondary prevention of cardiovascular events.
Across 12 RCTs (n=22,983), low-dose colchicine reduced myocardial infarction (RR 0.74) and stroke without increasing serious adverse events; effects on all-cause and cardiovascular mortality were neutral to modest. Gastrointestinal events were more frequent but generally mild and transient.
Impact: This high-quality synthesis clarifies benefits and harms, strengthening the evidence base for adding colchicine to secondary prevention regimens in appropriate patients.
Clinical Implications: Consider low-dose colchicine (0.5 mg daily) in secondary prevention for patients at high ischemic risk with acceptable GI tolerability and without contraindications; monitor for gastrointestinal symptoms and drug interactions.
Key Findings
- Low-dose colchicine reduced MI risk (RR 0.74; high-certainty evidence).
- Stroke was reduced; serious adverse events were not increased versus control.
- Gastrointestinal adverse events (e.g., diarrhea, nausea) were more common but typically mild/transient.
Methodological Strengths
- Cochrane-standard systematic review with comprehensive search and RoB2 assessment
- GRADE assessment of certainty and random-effects meta-analytic approach
Limitations
- Heterogeneity in populations, dosing schedules, and background therapies
- Mortality effects remain less definitive; adherence and long-term tolerability vary
Future Directions: Define optimal patient selection (e.g., residual inflammatory risk), duration, and integration with contemporary antithrombotic and lipid-lowering therapies; monitor rare toxicity in pragmatic trials.
RATIONALE: People with cardiovascular disease are at risk of recurrent major adverse cardiovascular events, and chronic low-grade inflammation may be a major underlying factor. Treatment with low-dose colchicine has been proposed for the secondary prevention of cardiovascular events in individuals at high cardiovascular risk. A previous Cochrane review showed considerable uncertainty regarding the benefits and harms of this approach. OBJECTIVES: To evaluate the benefits and harms of low-dose colchicine in the prevention of cardiovascular events in adults with a history of stable CVD or following myocardial infarction or stroke. SEARCH METHODS: We conducted a comprehensive search of the literature until February 2025 using Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the drugs@FDA database, references of key papers, and references of included studies. ELIGIBILITY CRITERIA: Randomised controlled trials (RCTs) comparing the use of low-dose colchicine for a minimum of six months versus any control intervention in patients of any age with cardiovascular disease (i.e. history of stable cardiovascular disease, previous myocardial infarction or stroke). OUTCOMES: Our critical outcomes were all-cause mortality, myocardial infarction, and serious adverse events. Our important outcomes were cardiovascular mortality, stroke, all-cause hospitalisations, coronary revascularisation (percutaneous coronary intervention (PCI)/angioplasty or coronary artery bypass graft (CABG)), quality of life, and gastrointestinal adverse events (i.e. diarrhoea, nausea, abdominal pain, or vomiting). RISK OF BIAS: Two authors independently assessed the risk of bias using the Cochrane RoB2 tool. SYNTHESIS METHODS: We conducted meta-analyses using the random-effects model. We generated forest plots to facilitate visualisation of the data. We did not perform any subgroup analysis. We used GRADE to assess the certainty of evidence for all critical outcomes and for cardiovascular mortality, stroke, and coronary revascularisation. This was carried out by two review authors working independently. INCLUDED STUDIES: We included 12 studies involving 22,983 randomised participants. The follow-up in the studies ranged from 6 to 80 months. Overall, 11,524 participants were assigned to low-dose colchicine treatment and 11,459 were assigned to a control intervention, which constituted either usual care plus placebo or usual care only. The doses of colchicine used were 0.5 mg once or twice daily. At baseline, the mean age of participants ranged from 57 to 74 years. Most participants (79.4%) were male. SYNTHESIS OF RESULTS: There is high-certainty evidence that low-dose colchicine treatment reduces the risk of myocardial infarction, with a risk ratio (RR) of 0.74 (95% confidence interval (CI) 0.57 to 0.96; 22,153 participants, 8 studies; I